FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling Compounded "semaglutide" is not FDA approved semaglutide.com BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs ProPublica